Navigation Links
Oramed's Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.
Date:12/21/2009

JERUSALEM, Israel, December 21 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that Dr Roy Eldor will present an overview of the clinical development of Oramed's Oral Insulin capsule. Dr. Eldor is the principal investigator for all of Oramed's clinical trials conducted at Hadassah Medical Center. He is a physician in the Diabetes Unit and Endocrinology Department of Hadassah Medical Center.

The conference will take place at the Wohl Center, Bar Ilan University, in Ramat Gan, Israel on December 21-23. Dr Eldor's presentation will be given on December 22 at 4:10 PM. He will be highlighting all of the clinical work that Oramed has completed to date, ranging from preclinical trials to its current Phase 2b trial.

"Oramed is honored to have been invited to present at this very important conference to share the clinical development of its Oral Insulin Capsule with the scientific community" says Dr Roy Eldor.

About the Conference:

The Conference will start to focus on the translation of "cutting edge" diabetes research into practical clinical care, with a particular emphasis on the organization and delivery of care in different health systems. Updates and overviews will be given by invited speakers from around the world, together with workshop and debate sessions and submitted oral and poster presentations.

For More information, please visit http://www.diabetescenter.org.il

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relations Contacts:

    Oramed Pharmaceuticals
    Tara Horn
    USA: +1-646-240-4193
    Int'l: +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mindray Medical to Exhibit at MEDICA 2009 in Dusseldorf, Germany
2. HCC Medical Insurance Services Selects Eldorado's Innovative Claims & Benefits Platform
3. Global Med Technologies(R) Licenses ElDorado(TM) Software Solutions to $3.5 Billion MedStar Health of Baltimore, MD
4. Global Med Technologies(R), Inc. Receives FDA 510(K) Clearance for ElDorado Donor(TM)
5. Global Med Technologies(R), Inc. Recieves FDA 510(K) Clearance for ElDorado Donor(TM)
6. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
7. IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care
8. Limeade Wellness Program Chosen to Serve Washington State Employees
9. Ten Finalists Chosen for Hutch Award(R)
10. M. D. Anderson team chosen to help navigate Cancer Genome Atlas
11. Michigan Dentist Chosen President-Elect of the American Dental Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever ... stuff. The season for grass pollen runs from May to July each year; with the ... victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered ... feedback from high school and college students who have participated in the program every ... and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear ... which retails normally at $29.97; for the remaining days of March, the price will ... reduced to a special price of just $10 (regular retail price $19.97). , The ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose Inhalers, Dry ... Respiratory Inhalers - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover how ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... infection and promote healing of the wound. The industry ... devices and products for the treatment of wounds caused ... that occur due to diseases such as diabetes, skin ... Europe was the largest ...
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies Corp. ... continues to develop collagenase based-therapies with a first ... marketed as XIAFLEX ®  in the U.S. and ... present a corporate overview at the upcoming 16 ... April 5, 2017 at 8:00 a.m. ET in ...
Breaking Medicine Technology: